The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 is in Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. OncoGenex' Forward Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our ongoing and anticipated product development activities, the timing of these activities, the potential benefits of our product candidates, the scope and value of our patents and the potential of our patent applications. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.